Since clinical NK cell products usually consist of cytokine-activated or cytokine-expanded NK cells [16, 39, 40], we investigated whether our observation that unactivated KIR–ligand-mismatched NK cells are better responders to myeloma than matched NK cells was also true for activated NK cells. Here, KIR3DL1 is linked to plasma cell myeloma.